Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Postal Realty Trust Fourth Quarter 2025 Earnings Call - Fully Funded $115M-$125M Acquisition Plan Backed by $271M Liquidity
Postal Realty beat 2025 targets across the board and is moving quickly to turn that strength into more scale. AFFO came in at $1.32 for the year with Q4 AFFO per share of $0.33, same-store cash NOI wa...
- Company exceeded 2025 guidance on multiple fronts; AFFO per share for Q4 2025 was $0.33 and full-year AFFO per share was $1.32, at the high end of guidance.
- Initial 2026 acquisition guidance is $115 million to $125 million, underwritten at a mid-7% weighted average cap rate and fully funded by recent equity and debt raises.
- 2025 acquisitions totaled $123.1 million across 216 properties, with a weighted average initial cash cap rate of 7.7% for the year.
- +11 more takeaways
Circle Q4 2025 Earnings Call - USDC Network Scales to $75B as Arc and AI-Agent Payments Move to Mainstage
Circle closed 2025 with a statement of scale, not just promise. USDC circulation hit roughly $75 billion, on-chain USDC activity approached $12 trillion for the year, and Q4 produced $770 million of r...
- USDC circulation ended 2025 at about $75.3 billion, up 72% year-over-year.
- On-chain USDC transaction volume hit nearly $12 trillion for the year, a 247% year-over-year increase, signaling surging velocity.
- Q4 total revenue plus reserve income was $770 million, up 77% year-over-year; Adjusted EBITDA was $167 million, up 412% year-over-year, with a 54% Adjusted EBITDA margin.
- +12 more takeaways
Camping World Holdings Q4 2025 Earnings Call - Accelerated Inventory Cleanse Lowers Near-Term EBITDA, Dividend Paused to Delever
Camping World closed 2025 with clear operational gains, but management is deliberately trading near-term profit for a cleaner balance sheet and more nimble inventory heading into what it expects will ...
- Full-year 2025 adjusted EBITDA grew over 35%, and same-store unit sales improved by more than 14%.
- Q4 2025 revenue was about $1.2 billion; Q4 adjusted EBITDA loss was $26.2 million versus a $2.5 million loss in Q4 2024.
- Management estimates severe weather in late January/early February caused an estimated shortfall of ~1,500 new and used unit sales, equating to roughly $13.5 million of foregone gross profit.
- +13 more takeaways
Steven Madden, Ltd. Q4 and Full Year 2025 Earnings Call - Tariff Turmoil Stops EPS Guidance as Branded Momentum and Kurt Geiger Offset Private Label Collapse
Steven Madden closed 2025 with a split personality. Q4 benefited from a full-quarter contribution from the Kurt Geiger acquisition and a late-year rebound in the Steve Madden brand, driving consolidat...
- Q4 consolidated revenue was $753.7 million, up 29.4% year-over-year; excluding Kurt Geiger, Q4 revenue declined 1.4%.
- Full-year 2025 revenue was $2.5 billion, up 11% versus 2024; excluding Kurt Geiger, 2025 revenue declined 6.6%.
- Company did not provide EPS guidance for 2026 because tariff policy remains highly uncertain, management says they cannot responsibly commit without clarity.
- +16 more takeaways
Alcon Q4 2025 Earnings Call - Launch Momentum from Unity and Tryptyr Powers 2026 Guidance
Alcon closed 2025 on clear product momentum, led by Unity equipment rollouts, PanOptix Pro adoption in the U.S., and an unexpectedly strong Tryptyr launch in dry eye. The quarter delivered $2.7 billio...
- Q4 sales of $2.7 billion, up 7% year over year, with full year free cash flow of $1.7 billion versus $1.6 billion in 2024.
- Surgical franchise delivered $1.5 billion in Q4, up 6%; implantables were $474 million, up 2%, while consumables were $794 million, up 5%.
- Equipment accelerated strongly, $277 million in Q4 and up 18% year over year, driven largely by Unity platform placements and the late-2025 launch of Unity CS.
- +16 more takeaways
Recursion Pharmaceuticals Q4 2025 Earnings Call - AI-enabled platform shows clinical proof in FAP, runway extended to early 2028
Recursion used the quarter to argue that its decade-long bet on an end-to-end AI platform is beginning to pay clinical and commercial dividends. The company reported a positive clinical proof of conce...
- Clinical proof of concept: REC-4881 (MEK1/2 inhibitor) delivered a positive Phase 2 POC in FAP with a median 43% polyp burden reduction at 4 mg QD and a 75% responder rate; durable reductions persisted after 3 months off treatment.
- Regulatory path: Recursion plans initial engagement with the FDA on a registrational path for REC-4881 in the first half of 2026; 18 and over cohort is already recruiting and dose optimization is underway.
- Partnership momentum: Recursion achieved its fifth milestone with Sanofi, bringing total partner inflows to over $500 million cumulatively; Sanofi deal alone has paid $100 million upfront plus approximately $34 million in milestones to date.
- +11 more takeaways
Gladstone Land Corporation Q4 2025 Earnings Call - Lease Shift to Participation Rents and Water Assets Mask Near-Term AFFO Pressure
Gladstone Land spent 2025 balancing portfolio pruning, cash conservation, and an operational pivot on permanent crop leases. Management sold six farms for about $95 million and a $21 million aggregate...
- Sold six farms in 2025 for roughly $95 million and recognized about $21 million of aggregate gains, while still owning ~99,000 acres across 144 farms.
- Portfolio water assets concentrated in California: ~56,000 acre-feet of storage, which management translates to about 18 billion gallons; water availability and snowpack are currently favorable.
- Management shifted several permanent-crop leases from fixed base rent to higher crop-share participation, reducing fixed cash rent but creating timing and lippage in revenue and AFFO recognition.
- +11 more takeaways
BMO Financial Group Q1 2026 Earnings Call - ROE Rises to 13.1%; U.S. Optimization 90% Complete, Loan Growth Expected in H2 2026
BMO posted a strong start to 2026, driven by record pre-provision, pre-tax earnings of CAD 4.1 billion, adjusted EPS of CAD 3.48 (up 15% YoY), and underlying ROE of 13.1% (up 180 bps YoY). Management ...
- Adjusted EPS of CAD 3.48, up 15% year-over-year; reported EPS CAD 3.39 after a CAD 202 million severance charge (CAD 147 million after tax) that reduced EPS by CAD 0.21.
- Record pre-provision, pre-tax (PPPT) earnings of CAD 4.1 billion, driven by record revenue across operating segments.
- Underlying ROE reached 13.1%, up 180 basis points year-over-year and 130 basis points sequentially; ROTCE 17.1%, up 220 basis points.
- +11 more takeaways
UFP Technologies Q4 2025 Earnings Call - Contract Extension and Dominican Republic Capacity Push Give Visibility Despite AJR Labor Drag and Ransomware
UFP delivered a strong 2025 in top-line growth and cash generation, while navigating a messy mix of operational shocks. Revenue jumped 19.5% to $602.8 million and EPS rose 15.4% for the year, mileston...
- Full-year revenue rose 19.5% to $602.8 million, nearly tripling revenue since 2021, with operating income and EPS up ~435% and ~419% respectively over that four-year span.
- 2025 EPS grew 15.4% despite absorbing $6.3 million of labor inefficiencies at the AJR St. Charles, Illinois facility; that drag reduced full-year gross margin to 28.3% (would have been 29.3% absent the extra labor costs).
- AJR E-Verify disruption remains the principal near-term operational headwind, with a $1.2 million hit in Q4 versus roughly $3 million in Q3, management expects Q1 2026 impact to be smaller and to diminish each quarter thereafter.
- +14 more takeaways
ODDITY Q4 2025 Earnings Call - Major ad-platform algorithm change drove abnormal CPA spike, pressuring near-term growth but not the long-term strategy
ODDITY closed 2025 with record revenue and profitability, but the quarter’s flavor is caution. The company reported $810 million in 2025 net revenue (up 25%), adjusted EBITDA of $163 million (20.2% ma...
- 2025 results were strong: net revenue $810 million, up 25% year-over-year, with adjusted EBITDA $163 million and adjusted diluted EPS $2.21 for the year.
- Q4 2025 net revenue was $153 million, up 24% year-over-year; Q4 adjusted EBITDA was $13 million and adjusted diluted EPS was $0.20.
- Gross margin for 2025 expanded to 72.7% (up 30 basis points); Q4 gross margin was 70.5%, down 220 basis points year-over-year driven partly by product mix.
- +16 more takeaways